Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02173379 · ClinicalTrials.gov registry record · NA
Absorb IV Randomized Controlled Trial
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 2,604
- Enrollment target
NCT02173379 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 2,604 participants.
The verdict
NCT02173379, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,604 participants
- Enrollment target
Study Summary
ABSORB IV is a prospective, randomized (1:1, Absorb BVS to XIENCE), single-blind, multi-center study, registering approximately 2610 subjects from approximately 140 sites in the United States and outside the United States. ABSORB IV is a continuation of ABSORB III (NCT01751906) trial which are maintained under one protocol because both trial designs are related. The data from ABSORB III and ABSORB IV will be pooled to support the ABSORB IV primary endpoint. Both the trials will evaluate the safety and effectiveness of Absorb BVS. The ABSORB IV Randomized Controlled Trial (RCT) is designed to continue to evaluate the safety and effectiveness as well as the potential short and long-term benefits of Abbott Vascular Absorb™ Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System (once commercially available), as compared to the commercially approved, control stent XIENCE.
Interventions
- DEVICE XIENCE
- DEVICE Absorb BVS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,604 participants |
| Start Date | 2014-07 |
| Est. Completion | 2022-04-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02173379
The ClinicalTrials.gov registry entry for NCT02173379 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2,604 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which XIENCE is the first listed.
NCT02173379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02173379 about?
NCT02173379 is a clinical study titled "Absorb IV Randomized Controlled Trial". ABSORB IV is a prospective, randomized (1:1, Absorb BVS to XIENCE), single-blind, multi-center study, registering approximately 2610 subjects from approximately 140 sites in the United States and outside the United States. ABSORB IV is a continuation of ABSORB III (NCT01751906) trial which are maint...
What is the current status of trial NCT02173379?
This trial is currently completed. It is a NA study. The enrollment target is 2,604 participants. The study started on 2014-07. Estimated completion is 2022-04-06.
What interventions are being tested in trial NCT02173379?
The interventions under investigation include: XIENCE (DEVICE), Absorb BVS (DEVICE).
Who is sponsoring clinical trial NCT02173379?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.